Search: (WFRF:(Hennekens C))
> (2005-2009) >
The CHARM program: ...
The CHARM program: study design leads to findings of clinical and public health importance
-
Hennekens, C. H. (author)
-
Pfeffer, M. A. (author)
-
- Swedberg, Karl, 1944 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
-
(creator_code:org_t)
- 2016-06-29
- 2007
- English.
-
In: J Cardiovasc Pharmacol Ther. - : SAGE Publications. - 1074-2484. ; 12:2, s. 124-6
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- In large-scale randomized trials and their meta-analyses, beta-adrenergic blockers and angiotensin-converting enzyme inhibitors provide statistically significant and clinically important additive mortality and morbidity benefits in the treatment of heart failure. The CHARM trials were designed to test whether the angiotensin-receptor blocker candesartan would provide statistically significant and clinically important additive mortality and morbidity benefits to patients with heart failure as an alternative or in addition to angiotensin-converting enzyme inhibitors. CHARM demonstrated that an angiotensin-receptor blocker at a proven dose is an effective and safe therapy as an alternative or in addition to angiotensin-converting enzyme inhibitors in patients with heart failure, 55% of whom were receiving beta-adrenergic blockers. These benefits include reductions in cardiovascular mortality rate as well as in hospitalization for heart failure. Such patients have a 50% mortality rate at 5 years, and heart failure is the leading cause of hospitalization for patients 65 years of age and older.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Adrenergic beta-Antagonists
- Aged
- Angiotensin II Type 1 Receptor Blockers/*therapeutic use
- Angiotensin-Converting Enzyme Inhibitors/therapeutic use
- Benzimidazoles/*therapeutic use
- Cardiac Output
- Low/*drug therapy/mortality
- Drug Therapy
- Combination
- Hospitalization
- Humans
- Meta-Analysis as Topic
- Randomized Controlled Trials as Topic
- Tetrazoles/*therapeutic use
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database